Every Form 4 that Alkermes Inc. plc (ALKS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ALKS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALKS filings page.
Alkermes plc executive David Joseph Gaffin reported multiple equity award transactions. On February 18 and 19, 2026, he exercised restricted stock unit awards into ordinary shares, with each unit converting into one ordinary share.
He acquired 7,673 ordinary shares and 6,355 ordinary shares through derivative exercises at a stated price of $0.00 per share. On the same dates, he disposed of 3,407 and 2,126 ordinary shares, respectively, to cover tax liabilities through share withholding. After these transactions, his directly held ordinary shares totaled 231,602. One award is fully vested, while another vests in four equal annual installments starting on February 19, 2026.
Alkermes plc Director and CEO Richard F. Pops reported two transactions in ordinary shares. On February 5, 2026, he acquired 149,580 ordinary shares at no cost from the vesting of performance-based restricted stock units granted in February 2023 after a three-year performance period.
On the same date, he disposed of 62,230 ordinary shares at $33.55 per share. Following these transactions, Pops beneficially owned 1,377,740 ordinary shares directly.
Alkermes plc senior executive Christian Todd Nichols reported equity transactions in company ordinary shares. On February 5, 2026, he acquired 21,127 ordinary shares at no cost upon vesting of performance-based restricted stock units granted in 2023 after a three-year performance period.
On the same date, he reported a disposition of 6,389 ordinary shares at $33.55 per share. Following these transactions, Nichols directly owned 100,946 ordinary shares of Alkermes plc.
Alkermes plc executive Blair Curtis Jackson reported new share awards and a related share disposition. On February 5, 2026, Jackson acquired 28,810 ordinary shares at no cost from the vesting of performance-based restricted stock units granted on February 23, 2023, covering a three-year period that ended December 31, 2025. The vesting followed the determination that certain performance goals were achieved and a relative total shareholder return adjustment was applied.
On the same date, Jackson disposed of 8,626 ordinary shares at $33.55 per share in a transaction coded "F," and held 221,552 ordinary shares directly after these transactions.
Alkermes plc executive Craig C. Hopkinson, EVP R&D and Chief Medical Officer, reported equity compensation activity in the company’s ordinary shares. On February 5, 2026, he acquired 25,352 ordinary shares at no cost upon vesting of performance-vesting restricted stock units granted on February 23, 2023.
The vesting followed achievement of pre-set performance goals and application of a relative total shareholder return modifier, and represents the final vesting event under the 2023 PRSU awards. On the same date, 7,454 shares were disposed of at $33.55 per share (code F), typically indicating shares withheld or sold to cover tax obligations, leaving 75,638 shares held directly.
Alkermes plc executive David Joseph Gaffin reported equity compensation activity. On February 5, 2026, he acquired 25,352 ordinary shares at no cost when performance-vesting RSUs granted on February 23, 2023 vested after a three-year performance period ending December 31, 2025.
The same day, he disposed of 7,619 ordinary shares at $33.55 per share in a transaction coded “F.” After these transactions, he directly beneficially owned 223,107 ordinary shares of Alkermes plc.
Alkermes plc executive Craig C. Hopkinson, EVP R&D and Chief Medical Officer, reported option exercises and share sales in Alkermes ordinary shares. On February 2, 2026, he exercised an employee stock option for 5,000 shares at an exercise price of $19.34, converting it into ordinary shares. The filing shows two same-day sales of ordinary shares: 5,000 shares sold at a weighted average price of $34.2449 and 4,000 shares sold at $33.54. These transactions were carried out under a Rule 10b5-1 trading plan adopted on March 14, 2025. Following the reported trades, Hopkinson directly owns 57,740 ordinary shares and holds 26,356 employee stock options that are fully vested in accordance with their terms.
Alkermes plc director Shane Cooke reported exercising employee stock options and selling the resulting shares. On 02/02/2026, he exercised 61,200 employee stock options at an exercise price of $31.64 per share as the options approached their 02/28/2026 expiration.
That same day, he sold 29,087 ordinary shares at a weighted average price of $34.3382 per share and 32,113 ordinary shares at a weighted average price of $34.7796 per share in multiple transactions. After these trades, Cooke directly owned 103,744 ordinary shares of Alkermes plc.
The filing notes that the exercise and sale of expiring options were executed under a Rule 10b5-1 trading plan adopted on 02/27/2025, and that the options were fully vested in accordance with their terms.
Alkermes plc executive Craig C. Hopkinson, EVP R&D and Chief Medical Officer, reported an options exercise and share sale. On 01/08/2026 he exercised an employee stock option for 5,000 ordinary shares at an exercise price of $19.34 per share and then sold 5,000 ordinary shares at a weighted average price of $30.001 per share, with individual sale prices ranging from $30.00 to $30.01.
Both the option exercise and the sale were carried out under a Rule 10b5-1 trading plan adopted by the reporting person on 3/14/2025, and the options exercised were fully vested in accordance with their terms. After these transactions, he directly owned 61,740 ordinary shares and 31,356 employee stock options.
Alkermes plc (ALKS) reported an insider transaction by its EVP R&D and Chief Medical Officer, Craig C. Hopkinson. On 11/03/2025, he exercised 5,000 employee stock options at $19.34 and, on the same date, sold 9,000 ordinary shares at a weighted average price of $30.3824.
Both the option exercise and the sale were made under a Rule 10b5-1 trading plan adopted on 3/14/2025. The filing notes the sale occurred in multiple transactions at prices ranging from $30.34 to $30.56. Following these transactions, he directly beneficially owned 69,740 ordinary shares. He also reported 40,104 derivative securities (stock options) remaining. The options exercised were fully vested and carry an expiration date of 02/22/2031.
Alkermes (ALKS): EVP R&D and Chief Medical Officer Craig C. Hopkinson reported insider transactions on 10/15/2025. He exercised 5,000 options at an exercise price of $19.34 and sold 9,000 ordinary shares at a weighted average price of $31.5307 (sold in multiple trades ranging from $31.51 to $31.60). Both the option exercise and the sale were effected pursuant to a Rule 10b5-1 trading plan adopted on 3/14/2025. Following these transactions, he directly beneficially owned 73,740 ordinary shares; derivative securities beneficially owned were 45,104.